Abstract
BackgroundPirfenidone is an oral antifibrotic agent that has been shown to reduce the decline in lung function in patients with idiopathic pulmonary fibrosis (IPF). We performed an integrated analysis of...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have